$CHRS
Coherus BioSciences, Inc.

2022 Q4 Form 10-Q Financial Statement

#000155837022016850 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $45.35M $45.40M $73.37M
YoY Change -38.19% -44.97% -33.54%
Cost Of Revenue $14.20M $35.23M $12.10M
YoY Change 17.33% 65.57% 3.45%
Gross Profit $31.15M $10.17M $61.27M
YoY Change -49.16% -83.4% -37.93%
Gross Profit Margin 68.68% 22.39% 83.5%
Selling, General & Admin $53.62M $44.83M $50.05M
YoY Change 7.13% 12.29% 32.76%
% of Gross Profit 172.14% 440.99% 81.69%
Research & Development $29.02M $45.81M $50.76M
YoY Change -42.83% -15.3% 13.82%
% of Gross Profit 93.17% 450.6% 82.85%
Depreciation & Amortization $1.050M $995.0K $836.0K
YoY Change 25.6% 11.55% -7.11%
% of Gross Profit 3.37% 9.79% 1.36%
Operating Expenses $82.64M $90.64M $100.8M
YoY Change -18.02% -3.59% 22.5%
Operating Profit -$51.49M -$80.45M -$39.55M
YoY Change 30.21% 145.37% -341.14%
Interest Expense -$9.385M $7.540M -$5.793M
YoY Change 62.01% 30.65% 1.63%
% of Operating Profit
Other Income/Expense, Net $2.008M $1.339M -$385.0K
YoY Change -621.56% 4363.33%
Pretax Income -$58.87M -$86.65M -$45.73M
YoY Change 28.75% 124.9% -523.38%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$58.87M -$86.65M -$45.73M
YoY Change 28.75% 124.9% -571.39%
Net Earnings / Revenue -129.81% -190.86% -62.32%
Basic Earnings Per Share -$1.11
Diluted Earnings Per Share -$0.76 -$1.11 -$595.0K
COMMON SHARES
Basic Shares Outstanding 77.78M 77.72M 76.79M
Diluted Shares Outstanding 77.75M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $191.7M $286.8M $417.2M
YoY Change -54.05% -38.81% -22.91%
Cash & Equivalents $63.55M $286.8M $417.2M
Short-Term Investments $128.1M $0.00 $0.00
Other Short-Term Assets $40.80M $42.57M $24.46M
YoY Change 66.77% 40.0% -2.14%
Inventory $38.79M $27.72M $37.64M
Prepaid Expenses
Receivables $110.0M $91.19M $123.0M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $381.2M $448.3M $602.3M
YoY Change -36.71% -33.4% -21.52%
LONG-TERM ASSETS
Property, Plant & Equipment $8.754M $9.571M $7.813M
YoY Change 12.04% 12.53% -22.7%
Goodwill $900.0K $943.0K
YoY Change -4.56% 0.0%
Intangibles $5.931M $2.620M
YoY Change 126.37% 0.0%
Long-Term Investments
YoY Change
Other Assets $8.668M $9.627M $10.03M
YoY Change -13.54% -6.19% -20.07%
Total Long-Term Assets $99.61M $102.6M $77.01M
YoY Change 29.35% 49.42% 3.83%
TOTAL ASSETS
Total Short-Term Assets $381.2M $448.3M $602.3M
Total Long-Term Assets $99.61M $102.6M $77.01M
Total Assets $480.8M $550.9M $679.3M
YoY Change -29.22% -25.73% -19.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.53M $9.917M $16.16M
YoY Change -28.67% -78.3% 6.3%
Accrued Expenses $50.10M $85.99M $48.13M
YoY Change 4.09% 87.64% 80.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.191M $741.0K
YoY Change 60.73% 23.5%
Total Short-Term Liabilities $138.7M $171.3M $165.3M
YoY Change -16.11% -46.52% 13.51%
LONG-TERM LIABILITIES
Long-Term Debt $472.5M $470.5M $408.8M
YoY Change 15.58% 66.9% 0.96%
Other Long-Term Liabilities $3.467M $102.0K $750.0K
YoY Change 362.27% -86.4% -28.64%
Total Long-Term Liabilities $3.467M $102.0K $750.0K
YoY Change 362.27% -86.4% -28.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $138.7M $171.3M $165.3M
Total Long-Term Liabilities $3.467M $102.0K $750.0K
Total Liabilities $618.3M $648.0M $581.6M
YoY Change 6.3% 6.07% 3.73%
SHAREHOLDERS EQUITY
Retained Earnings -$1.342B -$1.283B -$1.050B
YoY Change 27.79% 27.75% 37.64%
Common Stock $8.000K $7.000K $7.000K
YoY Change 14.29% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$137.4M -$97.13M $97.73M
YoY Change
Total Liabilities & Shareholders Equity $480.8M $550.9M $679.3M
YoY Change -29.22% -25.73% -19.29%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$58.87M -$86.65M -$45.73M
YoY Change 28.75% 124.9% -571.39%
Depreciation, Depletion And Amortization $1.050M $995.0K $836.0K
YoY Change 25.6% 11.55% -7.11%
Cash From Operating Activities -$99.95M -$37.09M -$52.32M
YoY Change 91.03% -370.51% -258.07%
INVESTING ACTIVITIES
Capital Expenditures $87.00K -$457.0K -$468.0K
YoY Change -118.59% 75.1% -48.0%
Acquisitions
YoY Change
Other Investing Activities -$129.8M $0.00 $108.0M
YoY Change -220.24% -100.0% -48.84%
Cash From Investing Activities -$129.9M -$457.0K $107.5M
YoY Change -220.85% -102.86% -48.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.593M 48.87M 1.487M
YoY Change 343.38% 4338.42% -72.96%
NET CHANGE
Cash From Operating Activities -99.95M -37.09M -52.32M
Cash From Investing Activities -129.9M -457.0K 107.5M
Cash From Financing Activities 6.593M 48.87M 1.487M
Net Change In Cash -223.3M 11.32M 56.65M
YoY Change -494.07% -63.25% -77.22%
FREE CASH FLOW
Cash From Operating Activities -$99.95M -$37.09M -$52.32M
Capital Expenditures $87.00K -$457.0K -$468.0K
Free Cash Flow -$100.0M -$36.63M -$51.85M
YoY Change 92.93% -362.18% -252.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1985000
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77746895
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79013240
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77520244
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74984811
dei Entity Central Index Key
EntityCentralIndexKey
0001512762
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76930096
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77770593
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.22
dei Entity File Number
EntityFileNumber
001-36721
dei Entity Registrant Name
EntityRegistrantName
Coherus BioSciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3615821
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77777938
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Address Address Line1
EntityAddressAddressLine1
333 Twin Dolphin Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
649-3530
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CHRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
286805000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417195000
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
91186000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
123022000
CY2022Q3 us-gaap Inventory Net
InventoryNet
27719000
CY2021Q4 us-gaap Inventory Net
InventoryNet
37642000
CY2022Q3 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
20633000
CY2021Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13666000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21932000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10798000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
448275000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
602323000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9571000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7813000
CY2022Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
77438000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
55610000
CY2022Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
5996000
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
3563000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9627000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10025000
CY2022Q3 us-gaap Assets
Assets
550907000
CY2021Q4 us-gaap Assets
Assets
679334000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9917000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16159000
CY2022Q3 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
54021000
CY2021Q4 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
79027000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21391000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22014000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
85990000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48127000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
171319000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
165327000
CY2022Q3 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
245246000
CY2021Q4 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
75513000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
225250000
CY2021Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
332767000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76930096
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1185868000
CY2022Q3 us-gaap Interest Expense
InterestExpense
7540000
CY2021Q3 us-gaap Interest Expense
InterestExpense
5771000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1147843000
us-gaap Interest Expense
InterestExpense
23089000
us-gaap Interest Expense
InterestExpense
17166000
CY2022Q3 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
6123000
CY2021Q4 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
7251000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
102000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
750000
CY2022Q3 us-gaap Liabilities
Liabilities
648040000
CY2021Q4 us-gaap Liabilities
Liabilities
581608000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77770593
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1282738000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1049854000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-97133000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
97726000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
550907000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
679334000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
45424000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
82503000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
165690000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
253180000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35234000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
21280000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55881000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45487000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45808000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54085000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
170336000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
312343000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
44831000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39925000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
144860000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
119661000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
125873000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
115290000
us-gaap Costs And Expenses
CostsAndExpenses
371077000
us-gaap Costs And Expenses
CostsAndExpenses
477491000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-80449000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32787000
us-gaap Operating Income Loss
OperatingIncomeLoss
-205387000
us-gaap Operating Income Loss
OperatingIncomeLoss
-224311000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.22
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77746895
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1339000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79013240
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77520244
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74984811
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-86650000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1814000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38528000
us-gaap Net Income Loss
NetIncomeLoss
-232884000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-172947000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4429000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-86650000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38528000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-232884000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-241375000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-86650000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38528000
us-gaap Net Income Loss
NetIncomeLoss
-232884000
us-gaap Net Income Loss
NetIncomeLoss
-241375000
us-gaap Net Income Loss
NetIncomeLoss
-241375000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-86650000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-38534000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-232884000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-241378000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
97726000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-96084000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
544000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2658000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13037000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
12563000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50150000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
642000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1655000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13935000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-22629000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-86650000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79000
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
321000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12388000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-97133000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
280974000
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1730000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16982000
us-gaap Inventory Write Down
InventoryWriteDown
5192000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-37000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
127671000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5631000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3150000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29900000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4009000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40903000
chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
35000000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11512000
us-gaap Share Based Compensation
ShareBasedCompensation
40418000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-3210000
us-gaap Inventory Write Down
InventoryWriteDown
26000000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
40000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
156220000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38528000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1288000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11786000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
130760000
us-gaap Profit Loss
ProfitLoss
-232884000
us-gaap Profit Loss
ProfitLoss
-241375000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2649000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2618000
us-gaap Share Based Compensation
ShareBasedCompensation
39011000
chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
136000000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
chrs Other Noncash Adjustments
OtherNoncashAdjustments
1844000
chrs Other Noncash Adjustments
OtherNoncashAdjustments
2708000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-31849000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-20722000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
37556000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2936000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
6967000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2884000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12509000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4590000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-6149000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
30495000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
-25006000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
3215000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-623000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-3451000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
32317000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
16526000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-141171000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14890000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1952000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
821000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
171779000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
62700000
chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
35000000
chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
136000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36952000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-245900000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417195000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
240679000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40903000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
631000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9726000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1655000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1985000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3621000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1730000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
109000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
81750000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-861000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-492000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47733000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50392000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-130390000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-180618000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
541598000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
287245000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360980000
CY2022Q3 chrs Product Pipeline Number Of Drug Candidates
ProductPipelineNumberOfDrugCandidates
3
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.</p>
CY2021Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
109723000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
426962000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-7300000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
541158000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
541598000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
286805000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360540000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
440000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
440000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
287245000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360980000
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
45400000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
165700000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
82500000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
253200000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
446720000
CY2022Q3 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
82665000
CY2020Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
123398000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
520917000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-8715000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
516557000
CY2021Q3 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
119043000
CY2022Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
10432000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4870000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
77296000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
65117000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
17429000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
23265000
CY2022Q3 us-gaap Inventory Gross
InventoryGross
105157000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
93252000
CY2022Q3 us-gaap Inventory Write Down
InventoryWriteDown
26000000.0
CY2021Q3 us-gaap Inventory Write Down
InventoryWriteDown
5200000
chrs Estimated Increase Decrease In Net Income Loss
EstimatedIncreaseDecreaseInNetIncomeLoss
26000000.0
CY2022Q3 chrs Estimated Increase Decrease In Net Income Loss
EstimatedIncreaseDecreaseInNetIncomeLoss
26000000.0
CY2022Q3 chrs Estimated Increase Decrease In Net Income Loss Per Share Basic And Diluted
EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted
0.33
chrs Estimated Increase Decrease In Net Income Loss Per Share Basic And Diluted
EstimatedIncreaseDecreaseInNetIncomeLossPerShareBasicAndDiluted
0.34
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
26000000.0
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
200000
CY2022Q3 us-gaap Inventory Net
InventoryNet
27719000
CY2021Q4 us-gaap Inventory Net
InventoryNet
37642000
CY2022Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
77438000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
55610000
CY2022Q3 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
105157000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48127000
CY2021Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
93252000
CY2022Q3 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
20600000
CY2022Q3 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
16600000
CY2022Q3 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
4000000.0
CY2021Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
13700000
CY2021Q4 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
8300000
CY2021Q4 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
5400000
CY2021Q1 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-3200000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
28890000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
24662000
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
19319000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
16849000
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
9571000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7813000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2600000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2600000
CY2022Q3 chrs Accrued Commercial And Research And Development Manufacturing Liabilities Current
AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
51523000
CY2021Q4 chrs Accrued Commercial And Research And Development Manufacturing Liabilities Current
AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
30541000
CY2022Q3 chrs Accrued Co Development Costs Payable To Junshi Biosciences
AccruedCoDevelopmentCostsPayableToJunshiBiosciences
17544000
CY2021Q4 chrs Accrued Co Development Costs Payable To Junshi Biosciences
AccruedCoDevelopmentCostsPayableToJunshiBiosciences
1926000
CY2022Q3 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
4097000
CY2021Q4 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
3492000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12826000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12168000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
85990000
CY2022Q1 chrs Collaboration Agreement Option Exercise Fee Per Program
CollaborationAgreementOptionExerciseFeePerProgram
35000000.0
CY2020Q2 us-gaap Share Price
SharePrice
14.815
CY2022Q3 us-gaap Share Price
SharePrice
9.61
CY2022Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
9448000
CY2022Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
28740000
CY2022Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
911000
CY2022Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
911000
CY2022Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
208000
CY2022Q3 us-gaap Purchase Obligation
PurchaseObligation
40218000
CY2022Q2 us-gaap Product Liability Contingency Loss Exposure Not Accrued Best Estimate
ProductLiabilityContingencyLossExposureNotAccruedBestEstimate
14000000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36783266
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37875696
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38052771
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38076739

Files In Submission

Name View Source Status
0001558370-22-016850-index-headers.html Edgar Link pending
0001558370-22-016850-index.html Edgar Link pending
0001558370-22-016850.txt Edgar Link pending
0001558370-22-016850-xbrl.zip Edgar Link pending
chrs-20220930.xsd Edgar Link pending
chrs-20220930x10q.htm Edgar Link pending
chrs-20220930xex31d1.htm Edgar Link pending
chrs-20220930xex31d2.htm Edgar Link pending
chrs-20220930xex32d1.htm Edgar Link pending
chrs-20220930_cal.xml Edgar Link unprocessable
chrs-20220930_def.xml Edgar Link unprocessable
chrs-20220930x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
chrs-20220930_pre.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
chrs-20220930_lab.xml Edgar Link unprocessable